IC-OS International Cardio-Oncology Society

IC-OS Working Group Webinar - Cardiac Amyloidosis: Cardiac Imaging Pearls - September 2021

16 September

9:00 AM America/New_York

1H

Watch Recording
Webinar 2: Cardiac Amyloidosis: Cardiac Imaging Pearls Sept 16



This webinar will explore important tips and strategies to use for typical imaging tools that are employed in diagnosing CA.



Jointly provided by The France Foundation and the International Cardio-Oncology Society


Target Audience
This educational activity is intended for the members of the cardiology and oncology healthcare teams who treat patients with cardiac amyloidosis, including physicians (cardiologists and hematologists/oncologists) and advance practice providers (nurse practitioners and PAs).

Statement of Need
There are significant challenges associated with the diagnosis and management of cardiac amyloidosis. While considered rare, this condition is almost certainly significantly underdiagnosed. Cardiac amyloidosis is influenced by several factors (eg, sex, age, geographic location, genetic factors, etc), is clinically heterogeneous, and can present as a number of other disorders (with subsequent delayed or misdiagnosis), and can take several years and visits to several different specialists before an accurate diagnosis is made.

Early diagnosis and intervention is critical (including distinguishing ATTR from AL and other amyloidoses), yet does not occur, typically as a consequence of the heterogeneity of the disease. Therapeutic options are indication-specific and are limited, but there are new and emerging agents with which clinicians may not be familiar. Given the limited awareness of CA, there is a significant need for education about CA and the importance of early multidisciplinary diagnosis and management, so that patients can have the best possible outcomes.

Educational Activity Learning Objective
Upon completion of this course, the participants should be able to:
Diagnose cardiac amyloidosis in a timely fashion

Activity Faculty
Ashutosh Wechalakar, MD
Ashutosh Wechalekar is Professor of Medicine and Haematology at University College London and Honorary Consultant Haematologist at University College London Hospital/Royal Free Hospital, London, UK.


Margot Davis, MD

Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul’s Hospital, a Clinical Assistant Professor at the University of British Columbia, and Director of the UBC Cardiology-Oncology Program.







Credit Designation
Physicians:
The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Method of Participation/How to Receive Credit


Review the activity objectives and CME/CE information.

Participate in the CME/CE activity.

Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.



Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France Foundation and the International Cardio-Oncology Society require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. [TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
• Faculty and activity staff disclosures will be provided prior to the start of the activity.


Disclosure of Unlabeled Use
TFF and IC-SO require that CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-SO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Commercial Support Acknowledgment
This activity is supported by an educational grant from Janssen and Eidos Therapeutics Inc.
Videos open video

IC-OS International Cardio-Oncology Society

LIVE - IC-OS Working Group Webinar - Cardiac Amyloidosis: Cardiac Imaging...

open video

IC-OS International Cardio-Oncology Society

IC-OS Working Group Webinar - Cardiac Amyloidosis: Cardiac Imaging Pearls -...

Speakers

Ashutosh Wechalekar

Ashutosh Wechalekar is Professor of Medicine and Haematology at University College London and Honorary Consultant Haematologist at University College London Hospital/Royal Free Hospital, London, UK. His clinical and research is focused on amyloidosis with a particular interest in cardiac amyloidosis. He leads the AL program for UK. His is the director of the Jack O’Neil Amyloidosis laboratory which is focused on amyloid typing and genomics. He leads UK’s first dedicated amyloidosis treatment clinic at University College London Hospitals and is leading development of a UK National Amyloidosis Treatment Network. He leads AL amyloidosis treatment and research in the UK. His research interests including the development of better risk stratification of the disease, reducing early cardiac mortality in AL, imaging, clonal biology and new treatment strategies in AL amyloidosis. He leads on several national and international clinical trials in AL amyloidosis and myeloma at UCL and has published extensively in the respective areas.

Carol Whelan

Dr Carol Whelan was appointed as Consultant Cardiologist with an interest in imaging, heart failure and, in particular, cardiac amyloidosis, in October 2009 at the Royal Free London NHS Foundation Trust. She was appointed as Honorary Associate Professor at UCL in recognition for her work at the National Amyloidosis Centre. She was appointed as Trust lead for heart failure and chairs a weekly cross site meeting of the dedicated Heart Failure Clinical Pathways Group. Through the CPG, the team aims to harmonise the experience for patients with heart failure to achieve excellence in a quality service across the Trust. In November 2019, Dr Whelan was appointed as councillor on the board of the British Society for Heart Failure. She wrote the chapter on cardiac amyloidosis in the latest Oxford Textbook of Heart Failure and has published widely on this subject. As a clinical expert, she assisted the NICE committee in their evaluation of two novel treatments, inotersen and patisiran, for hereditary transthyretin amyloidosis. These have both been approved in the UK.

Margot Davis

Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul’s Hospital, a Clinical Assistant Professor at the University of British Columbia, and Director of the UBC Cardiology-Oncology Program. She attended medical school and completed her Internal Medicine residency and Cardiology fellowship at the University of British Columbia. She then completed fellowships in Advanced Heart Failure & Transplant Cardiology and Cardio-Oncology & Cardiac Amyloidosis at Stanford University School of Medicine. She obtained her Master of Science degree in clinical epidemiology at the Harvard School of Public Health. Dr. Davis is Co-Chair of the CCS/CHFS Position Statement on Cardiac Amyloidosis, a Primary Panel member of the CCS Cardio-Oncology Guidelines, and a Secondary Panel member of the CCS Heart Failure Guidelines. She is on the Executive Committee of the Canadian Heart Failure Society Board of Directors and she is Vice President of the Canadian Cardiac Oncology Network. Her research interests are focused on the prevention, diagnosis, and management of heart disease related to cancer therapy, cardiac amyloidosis, and advanced heart failure

Marianna Fontana

Dr. Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, where she is deputy head of Center and deputy clinical lead. She obtained her Medical degree (MD) and qualifications as a cardiologist at the University of Pisa. She was appointed Director of the UCL CMR unit at the RFH in 2015 and Professor of Cardiology in 2020. She was appointed deputy Head of Center for Amyloidosis and Acute Phase Proteins and deputy clinical lead of the National Amyloidosis Center in 2019. She was awarded with an intermediate fellowship from the British Heart Foundation in 2018. Her research interests include CMR wih multiparametric mapping and pathogenesis, diagnosis and treatment of cardiac amyloidosis.